Compare ZDGE & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | ALGS |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 34.6M |
| IPO Year | 2016 | 2020 |
| Metric | ZDGE | ALGS |
|---|---|---|
| Price | $3.00 | $6.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | ★ 192.8K | 108.5K |
| Earning Date | 06-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | 73.85 | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,398,000.00 | $2,186,000.00 |
| Revenue This Year | $3.27 | $32.20 |
| Revenue Next Year | $5.78 | $4.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.21 | $4.80 |
| 52 Week High | $4.70 | $13.69 |
| Indicator | ZDGE | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 68.55 |
| Support Level | $2.87 | $6.25 |
| Resistance Level | $3.16 | $6.82 |
| Average True Range (ATR) | 0.13 | 0.50 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 21.05 | 84.65 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.